- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Redwood City Today
By the People, for the People
Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing
Company expects growth in RNA medicines manufacturing as it scales its ECO Synthesis platform.
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
Codexis President and CEO Alison Moore outlined the company's strategic focus on RNA medicines manufacturing at a recent healthcare conference, emphasizing expected inflection points in 2026 tied to its ECO Synthesis platform and continued execution in its legacy pharma biocatalysis business. Moore discussed Codexis' market opportunity around limitations in current oligonucleotide manufacturing methods, the company's plans to scale its ECO Synthesis platform, and its engagement with contract development and manufacturing organizations (CDMOs).
Why it matters
Codexis sees significant growth potential in the RNA medicines market, which is expanding into larger patient population indications. However, the company faces challenges around scaling oligonucleotide production using traditional manufacturing methods. Its ECO Synthesis platform aims to address these limitations and position Codexis as a leader in innovative RNA medicines manufacturing technologies.
The details
Moore said Codexis expects some existing customers to move into 'more significant contracts' related to its ECO Synthesis manufacturing platform in 2026. The company also plans to progress toward a commercial licensing agreement with at least one CDMO. Codexis is currently operating its ECO Innovation Lab in Redwood City at a 100-gram scale and aims to reach kilo scale by the end of 2022. The company also plans to bring its own small manufacturing facility online by the end of 2027, targeting kilo-scale operations and 'tens of kilos' of output.
- Codexis expects inflection points related to its ECO Synthesis platform in 2026.
- Codexis aims to progress toward a commercial licensing agreement with at least one CDMO.
- Codexis' ECO Innovation Lab in Redwood City is currently operating at a 100-gram scale and the company aims to reach kilo scale by the end of 2022.
- Codexis plans to bring its own small manufacturing facility online by the end of 2027.
The players
Codexis
An American protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications.
Alison Moore
The President and CEO of Codexis.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
